Keith Carlton Takes Charge as Executive Chairman at Newronika

New Leadership at Newronika

Newronika is excited to introduce Keith Carlton as the new Executive Chairman, a pivotal appointment for the company as it advances in the rapidly evolving field of neuromodulation technology, particularly the adaptive deep brain stimulation system known as AlphaDBS™.

Strategic Growth and Experience

Keith Carlton brings with him a wealth of knowledge and experience from his successful career in the medical device industry. His leadership has consistently led to innovation and growth, attributes that Newronika values as it prepares to expand its reach globally.

Welcome from Leadership

Dr. Lorenzo Rossi, the Co-Founder and CEO, expressed enthusiasm about Carlton's appointment, emphasizing that his strategic vision is crucial for advancing AlphaDBS towards commercialization. "Keith's history of nurturing innovative technologies will play an essential role in enhancing treatment options for patients suffering from Parkinson's disease," he stated.

Community Confidence in Leadership

Carlo Sanfilippo, Senior Investment Manager at Indaco Venture Partners and board member, also welcomed Carlton, stating, "His experience and leadership will be instrumental as we navigate through the next phase of growth for the company." This confidence from invested members showcases the belief in Carlton's capabilities.

Transformative Potential of AlphaDBS

In his own words, Keith Carlton expressed excitement about joining Newronika at such a critical time. He highlighted the potential of the company's adaptive technology to set a new standard of care for neurological disorders. One of his immediate focuses will be to support the launch of an important Phase III pivotal trial in the U.S.

Recent Milestones and Future Directions

Newronika has achieved significant milestones recently, including receiving CE Mark approval for AlphaDBS, obtaining U.S. FDA IDE clearance, and successfully closing a €13.6 million Series B financing round. These accomplishments underline Newronika's commitment to transforming the landscape of neuromodulation therapy.

About Newronika

Newronika SpA stands as a beacon of innovation in deep brain stimulation technology. As a spin-off from Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and the University of Milan, the company is dedicated to improving patient outcomes through real-time neurophysiological feedback. Based in Milan, Italy, Newronika is poised for expansion as it continues to secure regulatory approvals and launch clinical initiatives.

Contact Information

For further inquiries, Lorenzo Rossi, PhD, the Co-Founder and CEO, remains accessible for communication regarding Newronika's pioneering technologies and the upcoming trials. He is dedicated to advancing the company's mission in enhancing the lives of patients through innovative solutions.

Frequently Asked Questions

What is the role of Keith Carlton at Newronika?

Keith Carlton has been appointed as the Executive Chairman, bringing extensive experience in leading medical technology firms.

What is AlphaDBS?

AlphaDBS is Newronika's proprietary adaptive deep brain stimulation system designed to optimize therapy for patients with neurological disorders.

What recent milestones has Newronika achieved?

Newronika received CE Mark approval for AlphaDBS, achieved U.S. FDA IDE clearance, and closed a significant Series B financing round.

Who expressed confidence in Keith Carlton's appointment?

Dr. Lorenzo Rossi, Co-Founder and CEO of Newronika, and Carlo Sanfilippo, Senior Investment Manager at Indaco Venture Partners, both voiced their support for Carlton.

Where is Newronika headquartered?

Newronika is headquartered in Milan, Italy, and is dedicated to advancing adaptive deep brain stimulation technology.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.